Overall, data indicated a much higher intra- and inter-patient genomic diversity in CTCs than in corresponding tumour biopsies at resistance to BRAF inhibitors, which may strongly contribute to CIN and impact tumour adaptation to therapy. Here, BRAF is linked to cervical squamous intraepithelial neoplasia.